A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Istiratumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CARRIE
- Sponsors Merrimack Pharmaceuticals
- 14 Aug 2018 Trial has been discontinued in Belgium.
- 01 Aug 2018 Trial has been discontinued in Germany.
- 25 Jun 2018 According to a Merrimack Pharmaceuticals media release, Merrimack plans to present the complete data from this Phase 2 study at an upcoming medical oncology meeting.